Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 Model.
about
A novel function for kojic acid, a secondary metabolite from Aspergillus fungi, as antileishmanial agentNon-invasive in vivo study of the Trypanosoma vivax infectious process consolidates the brain commitment in late infectionsAppraisal of a Leishmania major strain stably expressing mCherry fluorescent protein for both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasisAntileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major AmastigotesIs paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled studyA scoring method to standardize lesion monitoring following intra-dermal infection of Leishmania parasites in the murine ear.Early curative applications of the aminoglycoside WR279396 on an experimental Leishmania major-loaded cutaneous site do not impair the acquisition of immunity.Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial.Noninvasive biophotonic imaging for studies of infectious disease.Conditional gene deletion with DiCre demonstrates an essential role for CRK3 in Leishmania mexicana cell cycle regulation.Experimental infection of Phlebotomus perniciosus by bioluminescent Leishmania infantum using murine model and artificial feederCutaneous and mucocutaneous leishmaniasis: emerging therapies and progress in disease management.Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered In Vivo Screening Paradigm for Development of Drugs To Treat Cutaneous Leishmaniasis.Imaging of the host/parasite interplay in cutaneous leishmaniasis.Imaging host-Leishmania interactions: significance in visceral leishmaniasis.Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis.Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid.In vivo imaging of transgenic Leishmania parasites in a live host.Natural killer cells support the induction of protective immunity during dendritic cell-mediated vaccination against Leishmania major.[Leishmania epidemiology, diagnosis, chemotherapy and vaccination approaches in the international network of Pasteur Institutes].Use of In Vivo Imaging System Technology in Leishmania major BALB/c Mouse Ear Infection Studies.Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation
P2860
Q27316554-EEE1AE96-8FB8-4A23-B67E-AFECBD459DEEQ28484843-6EBA95A9-EB5D-43C0-8F02-7EACE54D15E1Q28485377-51456CF2-9A6C-4670-8DCB-450D856008FEQ30488470-FA41D0CE-83C5-41B9-B90E-A41ACCABABEEQ33409844-BDE5DB2E-8464-428C-B906-AA42485808F9Q33438898-CA9B2F45-241E-4C5A-9929-9902F471D5C0Q33671863-EB0F891A-880C-406E-9685-1CA78A37F33AQ33676413-0447ECDC-65BF-49E8-AB49-E10CEB82C1B7Q34795683-8C371978-95BE-4DB9-8755-83289979A4D4Q34886067-3018457E-7D32-4EF8-9F83-D0A8D679101CQ37020701-5CC82BA6-8E63-42C3-B9EB-64B77FDD9CC8Q37167717-2F75E4BA-345B-433B-ACA9-59BD7D8011A6Q37693923-91949695-F582-4783-B50C-C9E148A41243Q37720821-DE06A717-0BF7-4F63-B05D-DABB2807DE3FQ37760628-469F4F79-4AB1-4E73-A360-CAE94E74903BQ38114928-F8259DB8-CF49-419E-9F85-458A59FBA7A5Q38195310-AF928A58-251F-4DD0-BA35-F2F2C6475CA0Q38342306-09D49FEA-C156-43C2-AD63-410B25547AD9Q42867804-6068F3D8-F9D3-42C3-8B50-7DF112BC3EF1Q42951271-2AD24B9A-BB29-4D7C-A036-D059205E7E4CQ44872017-16ECE4C9-DC7E-4750-8913-41CA22552398Q47290243-CCA4F433-45C9-4F08-81A0-ECDEFA1C9D63Q57822499-C4C5B485-634C-48BF-99D1-760152063EC9
P2860
Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 Model.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Optimization of topical therap ...... sing a reliable C57BL/6 Model.
@ast
Optimization of topical therap ...... sing a reliable C57BL/6 Model.
@en
Optimization of topical therap ...... sing a reliable C57BL/6 Model.
@nl
type
label
Optimization of topical therap ...... sing a reliable C57BL/6 Model.
@ast
Optimization of topical therap ...... sing a reliable C57BL/6 Model.
@en
Optimization of topical therap ...... sing a reliable C57BL/6 Model.
@nl
prefLabel
Optimization of topical therap ...... sing a reliable C57BL/6 Model.
@ast
Optimization of topical therap ...... sing a reliable C57BL/6 Model.
@en
Optimization of topical therap ...... sing a reliable C57BL/6 Model.
@nl
P2093
P2860
P50
P1476
Optimization of topical therap ...... sing a reliable C57BL/6 Model.
@en
P2093
Geneviève Milon
Ghislaine Guigon
Gloria Morizot
Hervé Lecoeur
P2860
P356
10.1371/JOURNAL.PNTD.0000034
P407
P577
2007-11-28T00:00:00Z